Molecular Pathogenesis and Therapeutics in Viral Hepatitis
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 31 July 2024 | Viewed by 3209
Special Issue Editors
2. Liver Diseases-Viral Hepatitis, Liver Unit, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain
Interests: viral hepatitis; hepatitis B and D viruses; gene therapy
2. Liver Disease Unit, Department of Microbiology, Fundació Hospital Universitari Vall d’Hebron, 08035 Barcelona, Spain
Interests: virology and infectious disease; HIV, viral hepatitis (especially HBV and HDV); SARS-CoV-2
Special Issue Information
Dear Colleagues,
Viral hepatitis affect hundreds of millions of people and represent a huge burden of disease worldwide. For this purpose, the WHO have launched a global strategy to eliminate viral hepatitis as a major health threat by 2030. However, important challenges remain to be overcome. Despite the high efficiency of current direct acting antivirals, the lack of a preventing vaccine against HCV is still an important drawback for its elimination in high-risk groups. On the other hand, although the availability of an effective vaccine against HBV and HDV, these infections still interest an extremely high number of people worldwide and they cannot be eradicated with the currently used antiviral strategies. HAV and HEV, although cause self-limited infections, can also be responsible for severe and fulminant cases of hepatitis, and even chronic hepatitis in presence of immune deficiency. Improving knowledge on hepatitis viruses and their interplay with the host is essential to understand how to control the infection and develop new curative antiviral strategies. In addition, there is an urgent need to scale up testing for HBV, HCV and HDV, to grant access to care to patients whom these infections go unnoticed. This Special Issue aims to open a window on the new findings on viral hepatitis virology, immunology and therapeutics, and the translation of that knowledge to diagnosis or clinical practice.
Dr. David Tabernero
Dr. Maria Francesca Cortese
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- viral hepatitis
- liver disease pathogenesis
- direct acting antivirals
- gene therapy
- immune system
- immunomodulatory treatments
- epidemiology
- viral quasispecies
